



UNITED STATES  
NUCLEAR REGULATORY COMMISSION  
REGION III  
2443 WARRENVILLE ROAD, SUITE 210  
LISLE, ILLINOIS 60532-4352

NOV 22 2004

Peter C. Conklin, M.D.  
Radiation Safety Officer  
Fairview Ridges Hospital  
201 East Nicollet Blvd.  
Burnsville, MN 55337

Dear Dr. Conklin:

Enclosed is Amendment No. 11 amending your NRC Material License No. 22-24306-01 in accordance with your request. Please note that the changes made to your license are printed in **bold** font.

Your request has been prepared in accordance with newly revised 10 CFR Part 35. 10 CFR Part 35 and NUREG 1556, Vol. 9, Final, should have been sent to you. Please use these new documents to prepare future licensing correspondence. These documents are also available on our website at:

<http://www.nrc.gov/reading-rm/doc-collections/cfr/part035/>

and

<http://www.nrc.gov/reading-rm/doc-collections/nuregs/staff/sr1556/v9/nureg-1556-9.pdf>

Please review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region III office at (630) 829-9887 so that we can provide appropriate corrections and answers.

Please be advised that your license expires at the end of the day, in the month, and year stated in the license. Unless your license has been terminated, you must conduct your program involving byproduct materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.
2. Notify NRC, in writing, within 30 days:
  - a. When an authorized user or Radiation Safety Officer permanently discontinues performance of duties under the license or has a name change; or
  - b. When the mailing address listed on the license changes.
3. In accordance with 10 CFR 30.36(d) and/or license condition, notify NRC, promptly, in writing, and request termination of the license when you decide to terminate all activities involving materials authorized under the license.

4. Request and obtain a license amendment before you:
  - a. Receive or use byproduct material for a clinical procedure permitted under Part 35 but not permitted by your license issued pursuant to this Part;
  - b. Permit anyone, except individuals described in 10 CFR 35.13(b), to work as an authorized user under the license;
  - c. Change Radiation Safety Officers;
  - d. Order byproduct material in excess of the amount, or radionuclide, or form different than authorized on the license;
  - e. Add or change the areas of use or address or addresses of use identified in the license application or on the license; or
  - f. Change ownership of your organization.
5. Submit a complete renewal application or termination request at least 30 days before the expiration date of your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of byproduct material after your license expires is a violation of NRC regulations. A license will not normally be renewed, except on a case-by-case basis, in instances where licensed material has never been possessed or used.

In addition, please note that NRC Form 313 requires the applicant, by his/her signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a notice of violation, or imposition of a civil penalty, or an order suspending, modifying or revoking your license as specified in the General Statement of Policy and Procedure for NRC Enforcement Actions.

Since serious consequences to employees and the public can result from failure to comply with NRC requirements, prompt and vigorous enforcement action will be taken when dealing with licensees who do not achieve the necessary meticulous attention to detail and the high standard of compliance which NRC expects of its licensees.

Please note that on October 25, 2004, the NRC suspended public access to ADAMS, and initiated an additional security review of publicly available documents to ensure that potentially sensitive information is removed from the ADAMS database accessible through the NRC's web site. Interested members of the public may obtain copies of the referenced documents for review and/or copying by contacting the Public Document Room pending resumption of public access to ADAMS. The NRC Public Document Room is located at NRC Headquarters in Rockville, MD, and can be contacted at 800-397-4209 or 301-415-4737 or [pdrc@nrc.gov](mailto:pdrc@nrc.gov).

Sincerely,

A handwritten signature in cursive script that reads "William P. Reichhold".

William P. Reichhold  
Materials Licensing Branch

License No. 22-24306-01  
Docket No. 030-18458

Enclosure: Amendment 11

**MATERIALS LICENSE**


Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

*PC 02130*

*313755*

<p>Licensee</p> <p>1. Fairview Ridges Hospital</p> <p>2. 201 East Nicollet Blvd. Burnsville, MN 55337</p>	<p>In accordance with the application dated <b>July 28, 2004,</b></p> <p>3. License number 22-24306-01 is amended in its entirety to read as follows:</p> <p>4. Expiration date February 28, 2005</p> <p>5. Pocket No. 030-18458 Reference No.</p>
---	--

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material identified in 10 CFR 35.500</p> <p>E. Iodine-125</p> <p>F. Palladium-103</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p> <p>D. Sealed sources identified in 10 CFR 35.500 (d)</p> <p>E. Sealed sources identified in 10 CFR 35.400 (f)</p> <p>F. Sealed sources identified in 10 CFR 35.400 (g)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. As needed</p> <p>D. As needed</p> <p>E. As needed</p> <p>F. As needed</p>
--	--	---



9. Authorized Use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
  - B. Any imaging and localization study permitted by 10 CFR 35.200.
  - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
  - D. Medical use described in 10 CFR 35.500 in devices which have been evaluated and approved for licensing purposes by the U.S. Nuclear Regulatory Commission or an Agreement State.
  - E. and F. Medical use as described in 35.400.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
22-24306-01

Docket or Reference Number  
030-18458

Amendment No. 11

CONDITIONS

10. Location of Use: 201 E. Nicollett Boulevard, Bursnville, MN

11. Radiation Safety Officer: Peter C. Conklin, M.D.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

Mary C. Foshager, M.D.

10 CFR 35.100, 35.200 and 35.300 (excluding iodine-131 for treatment of thyroid carcinoma).

Robert Lund, M.D.

10 CFR 35.100, 35.200, 35.300 and 35.500.

H. Joseph Spaeth, Jr., M.D.

10 CFR 35.100 and 35.200.

Kent D. Molde, M.D.

10 CFR 35.100 and 35.300.

Kevin D. Gustafson, M.D.

10 CFR 35.100, 35.200, 35.300 and 35.500.

Ronald E. DeCesare, M.D.

10 CFR 35.100, 35.200 and 35.500.

Dwight Hager, M.D.

10 CFR 35.100, 35.200, 35.300 and 35.500.

Jeffrey Lukens, M.D.

10 CFR 35.100, 35.200, 35.300 and 35.500.

Chris L. Palaskas, M.D.

10 CFR 35.100, 35.200, 35.300 and 35.500.

Richard Carlson, M.D.

10 CFR 35.100, 35.200, and 35.300.

Eric L. Bressler, M.D.

10 CFR 35.100, 35.200, and 35.500

James A. Kirkham, M.D.

10 CFR 35.100, 35.200, 35.300 and 35.500

Kenneth P. Korte, M.D.

10 CFR 35.100, 35.200, 35.300 and 35.500.

Peter C. Conklin, M.D.


10 CFR 35.100, 35.200, 35.300 (excluding iodine-131 for treatment of thyroid carcinoma) and 35.500.

Lorraine L. LaRoy, M.D.

10 CFR 35.100, 35.200, 35.300 and 35.500.

John J. Regan, Jr., M.D.

10 CFR 35.100, 35.300 and Technetium-99m for thyroid imaging.



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
22-24306-01

Docket or Reference Number  
030-18458

Amendment No. 11

<u>Authorized Users</u>	<u>Material and Use</u>
Robert E. Haselow, M.D.	10 CFR 35.300.
Douglas J. Olson, M.D.	10 CFR 35.300, and 35.400 (f) and (g).
John Bjorgen, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
John A. Kosiak, M.D.	10 CFR 35.300 (excluding iodine-131), and 35.400 (f) and (g).
Steven L. Benton, M.D.	10 CFR 35.200 and 35.200 limited to cardiovascular clinical studies.
Daniel Loes, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
Bernard C. Baier, M.D.	10 CFR 35.100, 35.200, 35.300 and 35.500.
Alan Laorr, M.D.	10 CFR 35.100, 35.200 and 35.500.
Richard F. Diaz, M.D.	10 CFR 35.300, and 35.400 (f) and (g).
Thomas Joseph Gilbert, M.D.	10 CFR 35.100, 35.200 and 35.500.
Bradley H. Kranendonk, M.D.	10 CFR 35.100 and 35.200.
Kendall J. Strand, M.D.	10 CFR 35.100 and 35.200.
Richard M. Thompson, M.D.	10 CFR 35.100 and 35.200.
Daniel L. Crosby, M.D.	10 CFR 35.100 and 35.200.
Steven C. Link, M.D.	10 CFR 35.100, 35.200 and 35.300.
Tore Dettlie, M.D.	10 CFR 35.100 and 35.200.
Linda K. Wilmarth, M.D.	10 CFR 35.300, and 35.400 (f) and (g).
<b>Kimberly K. McCollow, M.D.</b>	<b>10 CFR 35.300, and 35.400 (f) and (g).</b>


MATERIALS LICENSE  
SUPPLEMENTARY SHEET

License Number  
22-24306-01

Docket or Reference Number  
030-18458

Amendment No. 11

- 13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
- 14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
- 15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
  - A. Application dated August 28, 1994 and March 13, 1997 and May 14, 2002 (excluding QMP); and
  - B. Letters dated August 10, 1994, May 20, 1999 and October 24, 2001.



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date NOV 22 2004

By William P. Reichhold  
 William P. Reichhold  
 Materials Licensing Branch  
 Region III



**UNITED STATES  
NUCLEAR REGULATORY COMMISSION**

REGION III  
2443 WARRENVILLE ROAD, SUITE 210  
LISLE, ILLINOIS 60532-4352

October 8, 2004

Peter C. Conklin, M.D.  
Radiation Safety Officer  
Fairview Ridges Hospital.  
201 East Nicollet Boulevard  
Burnsville, MN 55337

SUBJECT: ACKNOWLEDGMENT OF CORRESPONDENCE  
(Letter Dated 7/7/2004)

Dear Peter C. Conklin, M. D.

In response to your request, we have completed the initial processing, which is an administrative review of your application for a(n):

New License                       Amendment                       Termination

No Administrative deficiencies were identified during this initial review. However, it should be noted that a technical review may identify omissions in the submitted information.

It appears that your request is routine (see 1-2 below, as applicable).

1. New and Amendment actions are normally processed within 90 days, unless we find major deficiencies, or policy issues requiring central program office assistance.
2. Termination actions are normally processed within 90 days, unless confirmatory surveys following decontamination/decommissioning activities are involved.

We will try to complete your request as soon as practicable. Any correspondence about this request should reference the control number(s). Please direct any questions concerning your request to the Materials Licensing Branch at (630) 829-9887.

Materials Licensing Branch

Mail Control Nos. 313755  
License Nos. 22-24306-01